# HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients

> **NCT00703872** · PHASE2 · UNKNOWN · sponsor: **Hepasome Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Oral HDV-Interferon + ribavarin
- **DRUG:** Injectable HDV-Interferon + ribavarin

## Key facts

- **NCT ID:** NCT00703872
- **Lead sponsor:** Hepasome Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703872, "HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00703872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*